Clinical trials: Infection Control
Bacterial Infection
Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)
To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection. To determine the acquisition rate of ESBL producing E. coli or K.
- Trial name
- NCT00254696
- Testing
- Extended-Spectrum-Lactamases (ESBLs)
- Volunteers
- 710 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
The study will evaluate the efficacy and safety of aprepitant injectable emulsion added to standard of care for hospitalized patients with COVID-19.
- Trial name
- NCT04470622
- Testing
- Aprepitant injectable emulsion
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Heron Therapeutics
Pharyngitis, Pain
Ambroxol Spray Sore Throat Study
The development of a new Ambroxol spray formulation for the treatment of sore throat pain associated with acute pharyngitis requires an initial phase II study to be conducted in order to select the most appropriate dose for pain…
- Trial name
- NCT01361802
- Testing
- Ambroxol Spray
- Where
- 15 sites in South Africa
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
DENV-3 Controlled Human Infection Model
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
- Trial name
- NCT06799741
- Testing
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Pertussis, Whooping Cough
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
This study will evaluate the safety and efficacy of 9 different vaccines containing aP (acellular pertussis) and TdaP (acellular pertussis, tetanus and diphtheria) in healthy subjects 18 to 40 years of age.
- Conditions
- Pertussis, Whooping Cough, Tetanus, Lockjaw
- Trial name
- NCT01529645
- Testing
- Acellular pertussis vaccine, Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed), Licensed TdaP booster vaccine
- Where
- Belgium
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Drug Safety
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis.
- Trial name
- NCT01319903
- Testing
- CaCP29, a humanized monoclonal antibody
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- InflaRx GmbH
Common Cold
Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)
The objectives of the study are to obtain knowledge about the safety in use, the patients' general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter (OTC) setting.
- Trial name
- NCT00480194
- Testing
- xylometazoline hydrochloride and ipratropium bromide (ZyComb)
- Volunteers
- 1,000 people
- Sponsor
- Nycomed
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of…
- Trial name
- PNEU-WAY (NCT03480802)
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of…
- Trial name
- NCT05219253
- Testing
- HZ/su
- Where
- 9 sites in India
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom.
- Trial name
- NCT04583995
- Testing
- SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine
- Where
- 33 sites in United Kingdom
- Volunteers
- 15,185 people, healthy volunteers welcome
- Sponsor
- Novavax
Hepatitis C
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
- Trial name
- CBZF961X2201 (NCT01825980)
- Testing
- BZF961, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Infection, Human Immunodeficiency Virus
Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)
This study employs a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group, non-inferiority design.
- Trial name
- NCT07711223
- Testing
- ACC017+FTC/TAF, DTG+FTC/TAF
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Monkeypox
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.
- Trial name
- NCT06771479
- Testing
- MVA strain monkeypox attenuated live vaccine (low dose), MVA strain monkeypox attenuated live vaccine (high dose)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Infection, Human Immunodeficiency Virus
A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
This study investigates the safety, tolerability and PKs of GSK2838232 with and without Ritonavir, and to evaluate different formulations of GSK2838232 in healthy subjects.
- Trial name
- NCT02289482
- Testing
- GSK2838232 PIB (SDD), GSK2838232 PIB (API), Ritonavir
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
The purpose of this study is to determinate the effectiveness, safety and tolerability (how well the body accepts the drug) of an investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) called TMC125.
- Trial name
- NCT00225303
- Testing
- TMC125
- Volunteers
- 116 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
SARS-CoV-2
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
The goal of this study is to add to the ongoing active and passive safety signal detection through signal refinement and, if needed, evaluation of potential safety signals related to taking the SARS-CoV-2 mRNA-1273 vaccine.
- Trial name
- NCT04958954
- Where
- United States
- Volunteers
- 50,000,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Meningitis, Cryptococcal, HIV Infections
A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS
To compare the safety and effectiveness of fluconazole with that of placebo as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002294
- Testing
- Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Bacterial Vaginosis, HUDC_VT
Clinical Study to Evaluate the Efficacy of HUDC_VT in Patients With Bacterial Vaginosis
The objective of the study is to confirm the pharmacological mechanism and evaluate the efficacy and safety after HUDC-VT administration compared to placebo in patients with bacterial vaginosis.
- Conditions
- Bacterial Vaginosis, HUDC_VT, Haudongchun
- Trial name
- NCT03357666
- Testing
- HUDC_VT(Glucose 200mg/Sodium chloride 200mg), HUDC_VT (Glucose 400mg/Sodium chloride 200mg), HUDC_VT (Glucose 400mg)
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Haudongchun Co., Ltd.